Misplaced Pages

JHW-007

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Atypical dopamine reuptake inhibitor

Not to be confused with JWH-007, a synthetic cannabinoid receptor agonist. Pharmaceutical compound
JHW-007
Identifiers
IUPAC name
  • (1R,5S)-3--8-butyl-8-azabicyclooctane
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC24H29F2NO
Molar mass385.499 g·mol
3D model (JSmol)
SMILES
  • CCCCN12CC1CC(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
InChI
  • InChI=1S/C24H29F2NO/c1-2-3-14-27-21-12-13-22(27)16-23(15-21)28-24(17-4-8-19(25)9-5-17)18-6-10-20(26)11-7-18/h4-11,21-24H,2-3,12-16H2,1H3/t21-,22+,23?
  • Key:HZEVDVGPBUFIAW-AIZNXBIQSA-N

JHW-007 is a cocaine analogue and a high affinity atypical dopamine reuptake inhibitor that is being researched for the treatment of cocaine addiction. JHW-007 has been found to blunt the psychostimulant effects of cocaine and reduce self-administration in rodents. JHW-007 exposure has been shown to block the conditioned place preference effects of cocaine. JHW-007 may directly antagonize the autoregulatory dopamine D2 receptor, a hypothesis that was developed following the observation of JHW-007's ability to inhibit D2 receptor-mediated currents in the midbrain.

Atypical dopamine reuptake inhibition

In contrast to cocaine and other cocaine-like dopamine reuptake inhibitors, JHW-007 binds to the dopamine transporter (DAT) in an occluded (closed) conformation, similar to (R)-modafinil. This type of receptor binding to the DAT has been observed to result in a gradual and sustained increase in extracellular dopamine in the nucleus accumbens. Peak levels of extracellular dopamine are also markedly reduced. Both modafinil and JHW-007 have been investigated for the treatment of cocaine addiction.

References

  1. ^ Avelar AJ, Cao J, Newman AH, Beckstead MJ (September 2017). "Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons". Neuropharmacology. 123: 410–419. doi:10.1016/j.neuropharm.2017.06.016. PMC 5546153. PMID 28625719.
  2. Velázquez-Sánchez C, Ferragud A, Murga J, Cardá M, Canales JJ (July 2010). "The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization". European Neuropsychopharmacology. 20 (7): 501–508. doi:10.1016/j.euroneuro.2010.03.005. PMID 20413276. S2CID 21330820.
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulatorsMonoamine releasing agentsAdrenergicsDopaminergicsSerotonergicsMonoamine metabolism modulatorsMonoamine neurotoxins
Stimulants
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Pyrrolidines
Racetams
Tropanes
Tryptamines
Others
ATC code: N06B
Categories:
JHW-007 Add topic